APRE: Promising WEE1 inhibitor shows efficacy and safety in biomarker-driven cancer trials
A precision oncology company presented clinical progress on its WEE1 inhibitor, showing promising efficacy and safety in biomarker-defined cancers, with further data and expansion cohorts expected later this year. The pipeline also includes ATR and p53 programs, with ongoing efforts to identify opt…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.